GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Neuraxis NRXS · USD

Health Care · US listing · 🇺🇸 United States

Compare

6.61

+5.93%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Neuraxis

From its filings with the US Securities and Exchange Commission

SEC filings

Neuraxis is based in Carmel, Indiana and is incorporated in Delaware. Its shares trade on NYSE under the ticker NRXS. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2025, it reported revenue of $3.6m and a net loss of $7.8m. At that date it held total assets of $6.4m and shareholders' equity of $3.4m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
9 Aug 2023
Employees
17
Head office
11611 N. MERIDIAN ST, CARMEL, IN, 46032
Incorporated in
DE
Classification
Electromedical & Electrotherapeutic Apparatus
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Bradley WatkinsIndependent Chairman of the Board, since 2023$110,000
  • Mr. Brian CarricoPresident, Chief Executive Officer, Director$578,376
  • Mr. Timothy HenrichsChief Financial Officer, since 2023$638,521
  • Dr. Adrian MirandaChief Medical Officer, Senior Vice President - Science and Technology$382,445
  • Dr. Thomas CarricoChief Regulatory Officer, Compliance Officer and Privacy Officer$368,914
  • Dr. Christopher BrownDirector
  • Dr. Gilad AharonIndependent Director
  • Ms. Kristin FergeIndependent Director$90,110
  • Ms. Beth KeyserIndependent Director$110,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Neuraxis Inc's PENFS technology advances neuromodulation therapies for children with chronic conditions.
  • The B-Stim device targets functional abdominal pain in IBS patients aged 11-18 years.
  • FDA pipeline includes chronic nausea, post-concussion syndrome, and chemotherapy-induced nausea indications.

Weaknesses

  • Neuraxis Inc employs only 17 full-time employees as of 2023.
  • The company's IPO occurred on 9 August 2023 with limited market presence.
  • Carmel, Indiana headquarters may limit access to major healthcare innovation hubs.

Opportunities

  • Expanding PENFS technology to address post-concussion syndrome and cyclic vomiting syndrome indications.
  • Growing demand for pediatric neuromodulation therapies in the US healthcare market.
  • FDA approval for IB-Stim device could unlock significant pediatric treatment options.

Threats

  • Limited employee count may hinder rapid product development and market expansion.
  • FDA regulatory delays could impact the timeline for new indications approval.
  • Competition in the pediatric neuromodulation sector remains unverified but potentially high.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.